Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.
The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...
The results shed light on how MariTide may measure up to weight loss injections from Novo Nordisk and Eli Lilly and other ...
Amgen's experimental drug MariTide helped overweight or obese patients lose up to 20% weight on average in a year-long ...
Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 ...
William Blair's assessment is that MariTide is an improvement on current obesity therapies with a profile that "will be ...
Wall Street Journal on MSN1d
Amgen Obesity Drug Cut Weight In Closely Watched StudyA highly anticipated obesity-drug candidate from biotech Amgen helped patients shed a significant amount of weight in a ...
Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential ...
An Amgen obesity drug helped participants lose a substantial amount of weight, but questions about how competitive it could ...
The company reported a Phase 2 study of its injectable MariTide medicine showed an approximately 20% average weight loss over one year for patients who were obese or overweight without diabetes. In ...
MariTide, which like Eli Lilly’s Zepound is a dual agonist of the GLP-1 and GIP receptors, demonstrated an average weight ...
Amgen stock tumbled Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback